Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

Clinical trial NCT05227144 · COMPLETED

Trial details

NCT number: NCT05227144
Sponsor: ORIC Pharmaceuticals
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Relapsed or Refractory Multiple Myeloma

Start date: 2022-01-06
Primary completion: 2025-03-03
Enrollment: 31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.